Location: Home / Volume 4, Part 2: Question 4
Part 2: Multiple Myeloma
Todd Zimmerman, MD
Dr. Zimmerman is an associate professor of medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.
Question 4
A 72-year-old woman with relapsed multiple myeloma presents for cycle 3 of bortezomib therapy. Her monoclonal protein with the first 2 cycles of therapy has dropped from 3.4 g/dL to 1.8 g/dL. She reports to the infusion nurse that she has burning pain in both of her feet that keeps her awake at night. She has residual paresthesias from prior thalidomide exposure, which has not worsened. What is the next most appropriate step in the management of this patient?
